Novo Nordisk EVP still believes in cardiovascular benefits of Wegovy

The notion that analysts had expected a study of the obesity drug’s cardiovascular effects to finish ahead of time gives the Danish pharmaceutical company no cause for concern.

Martin Holst Lange, executive vice president for development at Novo Nordisk | Photo: Novo Nordisk / PR

Novo Nordisk remains confident that obesity drug Wegovy will demonstrate positive cardiovascular benefits in people with obesity, according to the company’s executive vice president for development, Martin Holst Lange, speaking at a teleconference in connection with the company’s recently published financial report.

This assessment perhaps wasn’t a given considering that Novo Nordisk’s report laid out how the the external independent Data Monitoring Committee, DMC, had recommended the study continue as opposed to concluding early following a review of interim data back in July.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs